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Abstract
In the drive towards faster patient access to treatments, health technology assessment (HTA) agencies are increasingly faced 
with reliance on evidence from surrogate endpoints, leading to increased decision uncertainty. This study undertook an 
updated survey of methodological guidance for using surrogate endpoints across international HTA agencies. We reviewed 
HTA and economic evaluation methods guidance from European, Australian and Canadian HTA agencies. We considered how 
guidelines addressed the methods for handling surrogate endpoints, including (1) level of evidence, (2) methods of validation, 
and (3) thresholds of acceptability. Across the 73 HTA agencies surveyed, 29 (40%) had methodological guidelines that made 
specific reference to consideration of surrogate outcomes. Of the 45 methods documents analysed, the majority [27 (60%)] 
were non-technology specific, 15 (33%) focused on pharmaceuticals and three (7%) on medical devices. The principles of 
the European network for Health Technology Assessment (EUnetHTA) guidelines published in 2015 on the handling of 
surrogate endpoints appear to have been adopted by many European HTA agencies, i.e. preference for final patient-relevant 
outcomes and reliance on surrogate endpoints with biological plausibility and epidemiological evidence of the association 
between the surrogate and final endpoint. Only a small number of HTA agencies (UK National Institute for Care and Excel-
lence; the German Institute for Medical Documentation and Information and Institute for Quality and Efficiency in Health 
Care; the Australian Pharmaceutical Benefits Advisory Committee; and the Canadian Agency for Drugs and Technologies 
in Health) have developed more detailed prescriptive criteria for the acceptance of surrogate endpoints, e.g. meta-analyses 
of randomised controlled trials showing strong association between the treatment effect on the surrogate and final outcomes. 
As the decision uncertainty associated with reliance on surrogate endpoints carries a risk to patients and society, there is a 
need for HTA agencies to develop more detailed methodological guidance for consistent selection and evaluation of health 
technologies that lack definitive final patient-relevant outcome evidence at the time of the assessment.
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1  Background
A key issue in the increasing move towards early access to 
new and innovative healthcare technologies is the use of sur-
rogate endpoints to support licensing and coverage decisions 
of such technologies. Within this context [1, 2], a surrogate 
endpoint is defined as a biomarker (e.g. blood pressure) or 
an intermediate outcome (e.g. exercise capacity) that can 
substitute for a final patient-relevant outcome that includes 
mortality and health-related quality of life [3]. Disease 
areas with a strong tradition of surrogate endpoints include 
oncology (e.g. tumour response for overall survival) and car-
diovascular disease (e.g. blood pressure for cardiovascular 
mortality or morbidity). In clinical areas (e.g. dermatology 
or acute disease) where patient-relevant outcomes are rela-
tively quickly accrued, the need for surrogate endpoints is 
much less.
Many regulatory decisions across the world rely on surro-
gate endpoint evidence. Surrogate endpoints are the primary 
endpoints in almost half of the studies submitted to the US 
FDA for marketing approval of medicines [4, 5]. Recently, 
to inform the development pathways of medicines, the FDA 
published a list of accepted surrogate endpoints and dis-
ease areas that were the basis of approval or licensing of a 
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Key Points for Decision Makers 
Although surrogate endpoints enable faster trials and 
therefore faster access to treatment, they increase the 
uncertainty of coverage decisions on health technologies
Our survey shows that many international health technol-
ogy assessment (HTA) agencies currently lack detailed 
guidance for the evaluation of health technologies that 
rely on surrogate endpoint evidence
HTA agencies need to provide more detailed and pre-
scriptive guidelines for the consistent qualification and 
incorporation of surrogate endpoint evidence in the deci-
sion processes where the evidence on patient-relevant 
endpoints is lacking
Current best knowledge suggests that adequate 
approaches include evidence hierarchy frameworks, 
meta-regression analytical techniques and economic 
modelling methods that explicitly explore the uncertainty 
in the surrogate-to-final endpoint relationship
In 2009, Velasco Garrido and Mangiapane [17] published 
a survey of methodological guidance across international 
HTA agencies. Although 20 of 34 methods guidelines 
were reported to include surrogate endpoints, the depth 
and breadth varied considerably between documents. The 
authors concluded that “the role of surrogate outcomes in 
HTA is very limited”, with many agencies accepting health 
technologies based on surrogate endpoint evidence in the 
absence of definitive final endpoint data as exceptional and 
only when the validity of the surrogate endpoint has been 
proven. However, few agencies provided details on how such 
‘validity’ would actually be assessed.
Given recent developments in accelerated and adaptive 
licensing pathways, this study undertook an updated sur-
vey to gain a contemporary picture of methods for the han-
dling of surrogate endpoints by international HTA agencies. 
As this study was conducted within the European Union-
funded COMED (Pushing the boundaries of Cost and Out-
come analysis of Medical Technologies) project [18], we 
also sought to assess whether these methods for handling 
surrogate endpoints included specific provision for medical 
device technologies.
2  Methods
We sought to identify recommendations on approaching 
surrogate endpoint evidence in HTA as reflected by current 
public guidelines and technical documents from relevant 
HTA bodies.
2.1  Identification of Health Technology Assessment 
(HTA) Agencies
We updated the listing of European HTA agencies from the 
previous 2009 survey of surrogate endpoints [17] to include 
all organizations currently listed as members of three major 
HTA networks (as of March 2018): Health Technology 
Assessment International, the European network for Health 
Technology Assessment (EUnetHTA) and the International 
Network of Agencies for Health Technology Assessment. 
We included all HTA agencies unless they were patient 
organisations, organisations whose members/stakeholders 
were the industry, and university centres, hospitals and pro-
fessional organisations only involved in the production of 
HTA reports but not in policy guidance or methods develop-
ment. Additionally, we included Australian and Canadian 
HTA agencies as they have been established for many years 
and therefore reflect ‘mature HTA settings’, i.e. the Austral-
ian Pharmaceutical Benefits Advisory Committee (PBAC), 
the Australian Medical Services Advisory Committee 
(MSAC) and the Canadian Agency for Drugs and Technolo-
gies in Health (CADTH). For each HTA agency, we checked 
medicinal or a biological product under both the accelerated 
and the traditional approval pathways [6].
Whilst surrogate endpoints enable faster outcome accrual 
and therefore shorter clinical trials [7], reliance on such end-
points can be problematic if they fail to fully capture the 
complete risk–benefit profile of a health technology [8]. Sur-
rogate endpoints have been shown to overestimate interven-
tion effects [9] and, in some cases, lead to increased risk of 
harm [10, 11].
As the use of surrogate endpoints has become more com-
mon in the licensing of new health technologies [12], health 
technology assessment (HTA) agencies [12, 13] are under 
increasing pressure to utilise such evidence in their recom-
mendations that inform the coverage and funding of medicines 
and medical devices. Whether surrogate endpoint evidence is 
used to interpret clinical effect in the context of insufficient 
final patient-relevant endpoint information [14] or is trans-
lated to a different outcome (such as quality-adjusted life-year 
[QALY]) within an economic model [15], there is a need to 
ensure that the choice of surrogate is adequate. Therefore, it 
has been recommended that the use of surrogate endpoints be 
limited only to those that have been validated appropriately 
[1, 12, 16]. Such validation ideally requires (1) experimen-
tal evidence that demonstrates (2) an acceptable association 
between treatment-induced change on surrogate endpoint and 
treatment-induced change on final patient-relevant endpoint 
and (3) a quantification of the treatment-induced change on 
final patient-relevant endpoint based on the observed treat-
ment-induced change on surrogate endpoint [1].
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for the publicly available methodological guidance (in any 
language) either as guidelines or as methodological advisory 
documents (such as those of the UK National Institute for 
Health and Care Excellence [NICE] Decision Support Unit 
[19]). Agencies without available methods guidance were 
excluded.
2.2  Document Review and Data Extraction
We assessed the availability and the detail level of the guid-
ance on the use of surrogate endpoints evidence in HTA pro-
cesses that was provided by the included HTA organisations. 
Assessment included (1) terminology (including definitions) 
on the use of surrogate endpoints, (2) methods of surrogate 
validation and (3) methodological practices recommended 
in guidance documents.
2.3  Stage 1: Identification of HTA Agency Methods 
Guidance on the Use of Surrogate Endpoints
Websites of all included HTA agencies were screened using 
a combination of search terms (HTA, guidelines, methods, 
resources, publications, surrogate, intermediate and end-
points) to identify methods guidance availability and rel-
evant methods documents. This was supplemented by hand 
searching of the relevant link categories on the websites. 
Where necessary, agencies were also contacted directly to 
enquire about relevant documents. For each included agency, 
the following data were extracted: (1) name of agency and 
country, (2) name and website location of the methods docu-
ment, (3) language of the guideline, (4) text detailing use of 
surrogate endpoints (including location within the document 
and any citations referenced), (5) assessment of whether the 
guidance was specific to pharmaceuticals or medical devices 
or both and to certain disease areas (e.g. cancer). A data 
extraction form was developed and piloted by two authors 
(BG and OC) on a sample including documents in English, 
French and Italian to test the feasibility of the process and 
to ensure that captured data were appropriate and sufficient 
for the study’s objective. The revised extraction form was 
then used by a single reviewer with language skills for each 
agency (OC, CF, BG, MM, SR, FD, KS, SdG, AZ) between 
April and July 2018. A random sample of 20 documents 
was then checked by a second reviewer (OC, BG, SR, SdG). 
For the purposes of presentation in this report, all text was 
translated into English.
2.4  Stage 2: Detailed Analysis of Surrogate 
Methodological Advice
For each agency identified in stage 1 as including advice on 
the use of surrogate endpoints in their methods guidance, 
a more detailed data analysis framework was applied (see 
Table 1).
2.5  Data Analysis and Presentation
The findings of this survey are presented descriptively and 
in detailed summary results tables.
3  Results
3.1  Selection of HTA Agencies
A total of 73 HTA agencies met the inclusion criteria (see 
Fig. 1; Table 2); 29 were excluded because they had no 
published methodological guidance. Of the remaining 44 
agencies, 29 (66%) included consideration of the handling 
of surrogate endpoints in their methods guidance. These 29 
agencies included 18 European countries (Austria, Belgium, 
Bulgaria, Croatia, Germany, Spain, France, Germany, Hun-
gary, Ireland, Italy, Netherlands, Norway, Poland, Portugal, 
Sweden, Slovakia, United Kingdom), the EUnetHTA net-
work of agencies, and the agencies of PBAC, MSAC and 
CADTH. In total, 45 methodological guidance documents 
outlining the use of surrogate endpoints were included 
for analysis. Sources of these documents are presented in 
Table S1 in the electronic supplementary material (ESM).
3.2  Consideration of Surrogate Endpoints
The extent to which methodological guidelines provided 
specific consideration on the use of surrogate endpoints 
varied greatly between agencies. The guidance documents 
of three (10%) HTA agencies (the Agency for Quality and 
Accreditation in Health Care and Social Welfare in Croatia 
(AAZ), the Galician Agency for Health Technology Assess-
ment in Spain and the Norwegian Institute of Public Health) 
only mentioned surrogate endpoints in general terms and 
provided no specific methods guidance on their use.
Reflective of the collaborative partnership in the 
EUnetHTA project, methods guidance of many agencies 
was based on the guidance on surrogate endpoint methods 
published by the EUnetHTA in November 2015 [20]. Table 3 
provides a summary of key aspects of the EUnetHTA guid-
ance. Whilst the EUnetHTA guidelines state a preference 
for using final patient-relevant outcomes rather than sur-
rogate outcomes, they also recognise the need to use sur-
rogate/intermediate outcomes. For example, when evidence 
of the direct effect of the intervention on patient-relevant 
outcomes (such as mortality or health-related quality of life) 
is not available, the EUnetHTA guidelines propose criteria 
for acceptability of a surrogate endpoint: (1) a biological/
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clinical plausibility for the endpoint, (2) evidence of an 
association with the final patient-relevant endpoint and (3) 
consideration of wider risk–benefit and/or public health 
implications [21].
3.2.1  Definition for Surrogate Endpoints
In total, 13 methods documents (29%) provided explicit defi-
nitions for surrogate endpoints, many of which were consist-
ent with the EUnetHTA guideline definition, “biomarkers 
Table 1  Domains used to extract data from methods documents in stage 2
Domain Explanation
Definition Is a definition of surrogate endpoints provided as part of the document?
Examples Are examples of surrogate endpoints provided in the text of the document (e.g. progression-free survival as a 
surrogate endpoint for overall survival)?
Use of surrogates considered Are considerations on the use of surrogate endpoints included in the guidelines, such as recommendations to cau-
tion when including surrogate endpoints in the analysis?
Acceptability criteria Are acceptability criteria included in the guidelines (e.g. requirements to validate the surrogate endpoint used)?
Evidence strength assessment Is there a framework for quantifying the evidence on the surrogate–final outcome relationship? Level 1—evi-
dence demonstrating that treatment effects on the surrogate correspond to effects on the patient-related outcome 
(from clinical trials); level 2—evidence demonstrating a consistent association between surrogate outcome and 
final patient-related outcome (from epidemiological/observational studies); level 3—evidence of the biological 
plausibility of the relationship between surrogate outcome and final patient-related outcome (from pathophysi-
ological studies and/or understanding of the disease process)
Validation methods Are any validation methods prescribed (e.g. correlation of the effects on the surrogate endpoint and the effects on 
the clinical endpoint from meta-analysis of randomised trials)?
Validation values Are accepted cut-off values of the surrogate endpoint-to-final outcome association presented?
Fig. 1  Summary of agencies 
and documents selection. HTA 
health technology assessment
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and intermediate endpoints” that can “substitute for a clini-
cally meaningful (final) endpoint”. Guidelines from PBAC 
[22], MSAC [23] and CADTH [24] use similar definitions. 
For instance, surrogate outcomes are considered by CADTH 
as “a subset of intermediate outcomes” and are defined as 
“a laboratory measurement or a physical sign used as a sub-
stitute for a clinically meaningful end point that measures 
directly how a patient feels, functions, or survives” [24]. In 
their glossary of terms, PBAC defines surrogate outcomes 
as “a variable that is suspected, but not necessarily demon-
strated, to occur on the causal pathway from a clinical man-
agement or factor to the clinically relevant final outcome” 
and recommend the justification and validation of any sur-
rogate outcome used in the analysis [22].
3.2.2  Example of Surrogate Endpoints
In total, 18 documents (40%) provided specific examples 
of surrogate endpoints (e.g. “Blood pressure as a surrogate 
endpoint for cardiovascular mortality; bone mineral density 
as a surrogate for bone fracture; HIV1-RNA viral load as 
an indicator of viral suppression”, Health Information and 
Quality Authority, Ireland). A support document from the 
German Institute for Medical Documentation and Informa-
tion (DIMDI) [25] also provides examples where surrogate 
endpoints have been proven not to be good surrogates (e.g. 
increased bone density following treatment of osteoporosis 
with sodium fluoride did not result in an observed decrease 
in fractures). A total of 44 documents (98%) included some 
consideration of the use of surrogates in the analysis (e.g. 
“only use a surrogate outcome if it has a well-established 
link (i.e., validated) with one of (final) outcomes”, CADTH). 
While some guidelines seemed to implicitly consider the 
surrogate endpoints in a cost-effectiveness context (NICE, 
PBAC, CADTH), most did not seem to differentiate the 
interpretation of surrogate endpoints according to the 
domain (e.g. clinical efficacy, cost effectiveness, etc.). Only 
four guidelines (from the Austrian Ludwig Boltzmann Insti-
tute for Health Technology Assessment, the AAZ, the Pol-
ish Agency for Health Technology Assessment and Tariff 
System (AOTMiT) and CADTH) mentioned the use of sur-
rogate outcomes for safety.
3.2.3  Acceptability of Surrogate Endpoints
In total, 26 guidelines (52%) provided discussion on the 
acceptability of surrogate endpoints [e.g. “If there is data 
that validates a surrogate, then these will be assessed in 
terms of their relevancy and their credibility”, German Insti-
tute for Quality and Efficiency in Health Care (IQWiG)]. 
Nine (18%) clearly refer to the association between surrogate 
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3.3  Detailed Methodological Guidance 
on Surrogate Endpoints
In addition to the EUnetHTA guidelines, seven (15%) HTA 
agencies had methods guidance that included detailed meth-
odological consideration of surrogate endpoints: IQWiG 
(two documents), NICE, AOTMiT, the Portuguese National 
Authority of Medicines and Health Products (INFARMED), 
PBAC, MSAC and CADTH. These documents included 
recommendations of methods to be used for the validation 
of surrogate endpoints and, in two cases, cut-offs for the 
acceptance of surrogates according to their validation.
3.3.1  Methods for Validation of Surrogate Endpoints
Specific methods recommendations are listed in Table 4. 
EUnetHTA [20] and IQWiG [26] guidelines are the most 
detailed and prescriptive European guidelines, providing 
suggestions of methods for the validation of surrogate 
outcomes and defining necessary correlation levels for 
Table 3  Overview of EUnetHTA guidelines for surrogate endpoints
HbA1c glycated haemoglobin, ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, 
RCT randomised controlled trial
Use of surrogates considered? Yes (dedicated document)
Surrogate endpoints “should be adequately validated: the surrogate–final endpoint relationship must 
have been demonstrated based on biological plausibility and empirical evidence.”
Surrogate definition provided? Yes
“A surrogate endpoint is an endpoint that is intended to replace a clinical endpoint of interest that 
cannot be observed in a trial—it is a variable that provides an indirect measurement of effect in situ-
ations where direct measurement of clinical effect is not feasible or practical. (ICH guideline E9, 
Statistical Principles for Clinical Trials, 1998)
A surrogate endpoint may be a biomarker that is intended to substitute for a clinical endpoint. A sur-
rogate endpoint may also be a clinical endpoint that is used to replace the endpoint of interest, such 
as an intermediate clinical endpoint.”
“A biomarker can be defined as a characteristic that is objectively (reliably and accurately) measured 
and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmaco-
logic responses to an intervention” (Biomarkers Definitions Working Group, 2001)
“An intermediate endpoint is a clinical endpoint such as measure of a function or of a symptom 
(disease-free survival, angina frequency, exercise tolerance) but is not the ultimate endpoint of the 
disease, such as survival or the rate of irreversible morbid events (stroke, myocardial infarction)” 
(Temple et al. 1999)
Examples of surrogates listed? Yes
Example of surrogate endpoints: biomarkers (e.g. cholesterol level, HbA1c); examples of intermediate 
endpoints: disease-free survival, angina frequency, exercise tolerance
Acceptability criteria provided? Yes
“Before a biomarker can be accepted as a surrogate endpoint, there is a need to have confidence that 
changes in the biomarker reliably predict changes in the desired clinical endpoints” (EMA, 2007)
Evidence strength assessment provided? Yes
“The evidence for the validation of the surrogate–final outcome relationship has been presented by 
taking into account the level of evidence:
Level 1: evidence demonstrating that treatment effects on the surrogate endpoint correspond to effects 
on the patient-related clinical outcome (from clinical trials); comprises a meta-analysis of several 
RCTs and establishment of correlation between effects on the surrogate and clinical endpoint
Level 2: evidence demonstrating a consistent association between surrogate endpoint and final patient-
related endpoint (from epidemiological/observational studies); and
Level 3: only evidence of biological plausibility of relationship between surrogate endpoint and final 
patient-related endpoint (from pathophysiological studies and/or understanding of the disease pro-
cess)”
Validation methods provided? Yes
While the guidelines state that “currently, there is no systematic, transparent and widely agreed-upon 
process of biomarker validation”, they quote correlation of the effects on the surrogate and the 
effects on the clinical endpoint based on meta-analyses of several RCTs, as well as the surrogate 
threshold effect [39]
The document offers a selected bibliography addressing the statistical methods of surrogate validation
Validation values provided? Yes
Although only for information purposes: “There is no clear consensus of which correlation values 
are sufficient to assume adequate surrogacy, but values of between about 0.85 and 0.95 are often 
discussed”
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the association between surrogate and clinically relevant 
outcomes [27]. In contrast, NICE technology appraisal 
guidelines [28] focus on the decision uncertainty associ-
ated with evidence and this reflected in the economic mod-
elling of a technology and recommend that “in all cases, 
the uncertainty associated with the relationship between 
the end point and health-related quality of life or survival 
should be explored and quantified” [29]. PBAC guidance 
[22] contains a supplementary appendix that outlines a 
prescriptive approach to validating surrogate endpoints 
for decision modelling based on a four-step approach: (1) 
identify the surrogate endpoints and the corresponding final 
outcome; (2) establish the biological plausibility of the two, 
and present epidemiological evidence to support it; (3) pre-
sent randomised trial evidence to support the nature of the 
relationship; (4) translate the treatment effect on the surro-
gate endpoints to an estimate of the comparative treatment 
effect for the final outcome [22].
3.3.2  Specific Guidance for Disease Areas
In three cases, specific guidance on the use of surrogate 
endpoints in oncology was available: NICE [30] analysed 
the suitability of particular surrogate endpoints (such as 
progression-free survival for overall survival in cancer), and 
IQWiG [27] provided a detailed discussion on the potential 
use of surrogate outcomes in oncology. In CADTH guid-
ance, a document dedicated to the evaluation of oncology 
therapies [31] contained detailed discussion of acceptability 
of surrogate outcomes according to their correlation with 
patient outcomes and the treatment intent (curative, adju-
vant or palliative).
3.3.3  Specific Guidance for Medical Devices
Of the 45 methods documents analysed, 15 (33%) were 
exclusively intended for pharmaceuticals, and only three 
(7%) were intended exclusively for the evaluation of 
medical devices (NICE Medical Technology Evaluation 
Programme (MTEP), the State Institute for Drug Control 
in the Czech Republic and MSAC). Table 5 provides a 
comparison of the methods guidelines across HTA pro-
grammes aimed at evaluating either general health tech-
nologies or pharmaceuticals versus those for evaluating 
medical devices in the UK (NICE technology appraisal vs. 
MTEP) and Australia (PBAC vs. MSAC). Guidelines for 
medical devices appeared less specific and did not include 
any specific methodological recommendations beyond a 
general need to provide supporting evidence for surrogate 
endpoints (Table 5).
4  Discussion
Our updated international survey included 74 HTA agen-
cies, of which 29 (39%) had methodological guidance 
documents that included consideration of surrogate end-
points. Many of the European agencies’ methods guidelines 
appear to have been revised to reflect the principles of the 
EUnetHTA guidelines on surrogate endpoints published in 
2015 [20]. The EUnetHTA guidelines state a preference 
for evidence from final patient-relevant outcomes (such as 
mortality and health-related quality of life) and advise cau-
tious consideration when surrogate endpoints are used, i.e. 
use of ‘validated’ surrogate endpoints. However, although 
the EUnetHTA guidelines are a useful development, they 
do not provide any explicit criteria to establish whether or 
not a surrogate endpoint is valid. Furthermore, none of the 
HTA guidelines in our survey included a list of ‘accepted’ 
surrogate endpoints, i.e. surrogate endpoints for which the 
future use in an evaluation would not require justification.
We identified only five HTA agencies (IQWiG, DIMDI, 
NICE, PBAC and CADTH) with guidelines providing spe-
cific prescriptive methodological advice on the statistical 
methods that should be used for the validation and assess-
ment of acceptability of surrogate endpoints. Whilst there 
was a recognition across these guidelines of the lack of 
methodological consensus around the level of evidence 
necessary for the validation of surrogates, consensus was 
strong on the need for randomised trial data to support the 
association in the treatment effect between surrogate and 
final endpoints, including the use of meta-regression analy-
sis methods. However, only a IQWiG document currently 
discusses numerical values for an acceptable level of asso-
ciation (e.g. R2 trial > 0.49) [27]. Our results showed little 
difference in guidance between the use of surrogate end-
points for clinical effectiveness and for incorporation into 
economic models, with the exception of the NICE techni-
cal guidance approach, which focuses on the exploration of 
uncertainty in the surrogate-to-final-outcome relationship as 
part of the probabilistic sensitivity analysis. Since our study 
was conducted, the NICE decision support unit published 
another technical document [32]. This report focused on the 
use of multivariate meta-analytic methods for combining 
data from multiple correlated outcomes for the purpose of 
surrogate endpoint evaluation and suggested that, instead of 
criteria about the correlation, it is important to look at pre-
dicted estimates and their uncertainty because the strength 
(or weakness) of the surrogate relationship will manifest 
itself in the width of the predicted interval of the treatment 
effect on the final outcome.
The majority of methodological documents on surrogate 
endpoints identified in our study were intended to be applied 
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Table 4  HTA agencies with detailed methods for the handling of surrogate endpoints
Agency Methods for validation of surrogate endpoints Cut-offs for the acceptance of surrogate endpoints
MSAC (Australia) MSAC propose a three-step approach to validate the 
transformation of a surrogate endpoint to estimate final 
outcomes:
 Step 1 requires a systematic review “to examine whether 
epidemiological evidence and biological reasoning 
has established that there is a relationship between the 
surrogate outcome and the final outcome independent of 
any intervention”
 Step 2 requires a systematic review “to examine whether 
direct randomised trial evidence using other active 
medical services has shown that there is a basis to con-
clude that a treatment effect on the surrogate outcome 
has satisfactorily predicted a treatment effect on the 
final outcome. […] Based on this evidence, quantify 
the relationship between these treatment effects with an 
assessment of the uncertainty of the relationship”
 Step 3 requires an explanation “why this relationship 
between the treatment effects on these outcomes with 
these other active medical services is likely to apply 
to the proposed therapeutic medical service. […] At 
present, it is difficult to give categorical advice” [23]
Not reported
PBAC (Australia) PBAC propose a four-step approach to validating the use 
of a surrogate endpoint to predict a final outcome:
“A5.1—Define the PSM and the TCO
A5.2—Establish the biological reasoning for the link 
between the PSM and the TCO, including how pivotal 
the PSM is to the causation pathway of the TCO, and 
present epidemiological evidence to support this
A5.3—Present randomised trial evidence to support the 
nature of the PSM–TCO comparative treatment effect 
relationship
A5.4—Translate the comparative treatment effect on 
the PSM from the studies included in Part A, Subsec-
tion 2.2, to an estimate of the comparative treatment 
effect for the TCO.” [22]
Not reported
CADTH (Canada) “Validated surrogate outcomes are proven to be predictive 
of an important patient outcome. A surrogate outcome 
is valid only if there is a “strong, independent, consist-
ent association” with an important patient outcome, 
and there is “evidence from randomized trials that … 
improvement in the surrogate end point has consistently 
lead to improvement in the target outcome.” [24]
Not reported
DIMDI (Germany) No gold standard for the validation of surrogate end-
points, but approaches based on several studies, such as 
meta-analyses, are preferred
Regardless of statistical method used for validation, vali-
dation should be considered as technology specific [25]
Not reported
G-BA (Germany) Correlation from meta-analyses between effects on the 
surrogate outcome and the final outcome [39, 40]
Surrogate Threshold Effect [41]
Not reported
IQWiG (Germany) No ‘best’ method is defined, but correlation-based 
validation is the ‘preferred’ method, in the sense it has 
been most widely used in evaluations. Another option 
discussed is the surrogate threshold effect [26]
A support document [27] discusses threshold values 
reported in the literature, without enforcing them
“A correlation of R ≥ 0.85; R2 ≥ 0.72 measured at the lower 
bound of the 95% percentage interval allows to conclude 
that the validation study represents a high reliable result. 
This interval R < 0.85; R2 < 0.72 to R > 0.7; R2 > 0.49 
represents a medium reliable result between surrogate 
and patient-relevant endpoint. If a validation study shows 
high reliable results with statistically low correlation 
(R ≤ 0.7; R2 ≤ 0.49) measured at the lower bound of the 
confidence interval then the surrogate is not considered 
as a valid endpoint” [27]
1066 B. Grigore et al.
across health technologies (medicine, medical device or oth-
ers) and across medical conditions. Given that the develop-
ment and use of surrogate endpoints has become particularly 
common in oncology [33, 34], NICE, IQWiG and CADTH 
have published specific support documents for the use of 
surrogates in this clinical area [27, 30, 31]. Commonly used 
surrogate endpoints for the final outcome of overall survival 
in cancer include progression-free survival, disease-free sur-
vival and tumour response.
Pharmaceuticals and medical devices traditionally have 
different regulatory and evidence-generation pathways 
[35]. Given that various countries/agencies have separate 
HTA processes for the evaluation of medicines and medical 
devices, we could compare their methodological approaches 
to the consideration of surrogate endpoints [36]. The NICE 
technology appraisal is applicable to all medical tech-
nologies, whereas the NICE MTEP specifically considers 
medical devices and diagnostics. Similarly, in Australia, 
PBAC assesses pharmaceuticals and MSAC assesses medi-
cal devices. The PBAC and MSAC guidance on surrogate 
endpoints was similar, but we found more of a difference 
within NICE programmes. The NICE technology appraisal 
programme was much more detailed and directive in guid-
ance than the MTEP, reflecting the traditionally greater evi-
dence requirements for medicines than for devices. Whilst 
it might be expected that the evidence requirements for the 
use and validation of surrogate endpoints should not neces-
sarily differ between health technologies and across disease 
areas, we recognise there may be challenges in application. 
For example, given the current regulatory requirements, for 
specific medical devices, randomised controlled trial (RCT) 
(and sometimes, non-RCT)-level evidence may not be avail-
able at the time of HTA appraisal and even after it [35, 37]. 
It is likely that the requirement of ‘several RCTs’ for good 
Table 4  (continued)
Agency Methods for validation of surrogate endpoints Cut-offs for the acceptance of surrogate endpoints
EUnetHTA Correlation from meta-analyses of several RCTs between 
the effects on the surrogate and the effects on the clini-
cal endpoint
If there is no high correlation demonstrated, conclusions 
might still be made if the surrogate threshold effect is 
considered [41]
“Values of between about 0.85 and 0.95 are often dis-
cussed”
AOTMiT (Poland) “If the clinical effectiveness assessment is based on the 
results of surrogate endpoints, the clinical analysis must 
reliably demonstrate their relationship with the clini-
cally significant outcomes. Validation of the surrogate 
endpoints should be carried out in relation to the health 
problem in question.”
Cites EUNetHTA guidelines for methods
Not reported
INFARMED (Portugal) Seems to use the framework proposed by Bucher et al. 
[14]
“For a surrogate measure to be validated, the following 
questions should be positively answered:
1. Does a strong, consistent and independent association 
exist between the surrogate outcome and the clinically 
relevant outcome? This criterion is necessary but not 
sufficient in itself;
2. Are there any randomized studies on the same class 
of medicines, where improvements in the surrogate 
outcomes corresponded to improvements in clinically 
relevant outcomes?
3. Are there any randomized studies on different classes 
of medicines, where improvements in the surrogate 
outcomes corresponded to improvements in clinically 
relevant outcomes for the patient?”
To be considered as validated, a surrogate outcome must 
comply with criteria from 1 to 3. Verification of these 
criteria usually requires a meta-analysis of randomized 
studies
NICE (UK) Guidelines are not specific on the validation methods but 
emphasise that “in all cases, the uncertainty associated 
with the relationship between the end point and health-
related quality of life or survival should be explored and 
quantified”
Not reported
CADTH Canadian Agency for Drugs and Technologies in Health, DIMDI Institute for Medical Documentation and Information, EUnetHTA 
European network for Health Technology Assessment, G-BA The German Federal Health Care Joint Committee, IQWiG Institute for Quality and 
Efficiency in Health Care, MSAC Medical Services Advisory Committee, NICE National Institute for Care and Excellence, PBAC Pharmaceuti-
cal Benefits and Advisory Committee, PSM proposed surrogate measure, RCT randomised controlled trial, TCO target clinical outcome
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surrogate validation studies will never be satisfied for many 
indications requiring medical device-based procedures. 
When confronted with this challenge, there is a temptation 
to extrapolate validated surrogate endpoints from RCTs 
of medicines (e.g. the use of systolic blood pressure from 
RCTs of antihypertensive medicines) to medical-device-
based therapies (e.g. renal denervation therapy). However, 
we caution against this approach, given that different modes 
of action and classes of therapies are known to affect the 
surrogate-to-final-outcome relationship.
Our study provides a comprehensive contemporary 
review of methods guidance across international HTA agen-
cies on the use of surrogate endpoints. We explored a larger 
sample of agencies and documents than did the previous 
survey [17]. However, available resources (particularly time 
and linguistic access) limited the inclusion of non-European 
agencies to those of Australia and Canada. Furthermore, this 
survey only looked at publicly available documents and not 
at internal documentation that may be circulated within HTA 
agencies. As described in Sect. 2, methodological advisory 
documents [27, 30] were also considered, as—in our opin-
ion—they constitute important material to inform and com-
plement methods practice.
5  Conclusion
This updated survey of international HTA agencies dem-
onstrates an increase in the methodological guidance for 
the use of surrogate endpoints over the last decade, largely 
based on the adoption of EUnetHTA guidance on surrogates 
published in 2015. Nevertheless, we found considerable 
differences in the depth of this guidance, with only a few 
agencies currently having guidelines that provide detailed 
methodological advice on the statistical methods and metrics 
for surrogate validation that are deemed acceptable. Further 
methodological and policy research in the harmonization of 
approaches to surrogate outcomes evidence in healthcare 
decision making is warranted. The recent EU proposal of 
joint HTA clinical assessment [38] may provide the oppor-
tunity for implementation of a harmonised approach to the 
validation of the handling of surrogate endpoints across 
Europe. Our study also suggests an almost exclusive con-
sideration of surrogate endpoints from a clinical efficacy/
effectiveness perspective. Opportunities therefore remain to 
further clarify the effective and consistent use of surrogate 
endpoints in other HTA domains, especially safety and cost 
effectiveness.
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